Navigation Links
HIV drug could prevent cervical cancer
Date:5/3/2011

A widely used HIV drug could be used to prevent cervical cancer caused by infection with the human papilloma virus (HPV), say scientists.

University of Manchester researchers, working with colleagues in Canada, have discovered how the antiviral drug lopinavir attacks HPV by switching on a natural viral defence system in infected cells.

The study, published in the journal Antiviral Therapy, builds on the team's previous work in 2006 that first identified lopinavir as a potential therapeutic for HPV-related cervical cancer following laboratory tests on cell cultures.

"Since publishing our earlier work, we have now found that lopinavir selectively kills HPV-infected, non-cancerous cells, while leaving healthy cells relatively unaffected," said Dr Ian Hampson, from Manchester's School of Cancer and Enabling Sciences.

"This is a very significant finding as these cells are not cancer cells but are the closest thing to being like the cells found in a pre-cancerous HPV infection of the cervix. In addition we were also able to show that lopinavir kills these HPV-infected cells by re-activating a well-known antiviral system that is suppressed by HPV."

In many developing countries, HPV-related cervical cancer is still one of the most common women's cancers accounting for approximately 290,000 deaths per year worldwide. The same virus also causes a significant proportion of cancers of the mouth and throat in both men and women and this disease is showing an alarming increase in developed countries, such as the UK, where it is now more than twice as common as cervical cancer.

Although in the developed world vaccination programmes against HPV are well underway, these are not effective in women already infected with HPV. Furthermore, the current vaccines do not protect against all types of HPV and they are expensive, which will limit their use in countries with limited resources. A cheap and preferably self-administered treatment that could eliminate early-stage HPV infections before these have developed into cancers would therefore have distinct health advantages.

Dr Hampson said: "Our results suggest that for this drug to work against HPV it would be necessary to treat virus-infected cells of the cervix with roughly 10-15 times the concentration that is normally found in HIV-infected patients taking lopinavir as tablets. This implies that, for this treatment to work, it would need to be locally applied as a cream or pessary."

Co-author on the paper, Dr Lynne Hampson, added: "These results are very exciting since they show that the drug not only preferentially kills HPV-infected non-cancerous cells by re-activating known antiviral defence systems, it is also much less toxic to normal non-HPV infected cells.

"Lopinavir is obviously safe for people to take as tablets or liquid but our latest findings provide very strong evidence to support a clinical trial using topical application of this drug to treat HPV infections of the cervix."


'/>"/>

Contact: Aeron Haworth
aeron.haworth@manchester.ac.uk
44-161-275-8383
University of Manchester
Source:Eurekalert

Related medicine news :

1. Researchers discover mechanism that could convert certain cells into insulin-making cells
2. Pediatric flu vaccination: Understanding low acceptance rates could help increase coverage
3. Discovery could change the way doctors treat patients with cancer and autoimmune diseases
4. New class of cancer drugs could work in colon cancers with genetic mutation, U-M study finds
5. Protein levels could signal that a child will develop diabetes
6. Smoking Could Raise Odds for Advanced Kidney Cancer
7. Babies Persistent Fussiness Could Mean Behavioral Woes Ahead
8. Heart drugs could cut blood pressure risks in pregnancy
9. Alzheimers Cases Could Double With New Guidelines: Expert
10. Minimizing side effects from chemoradiation could help brain cancer patients live longer
11. Quality of parent-toddler relationship could affect risk for childhood obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... ... 25, 2017 , ... Republicans in the United States Senate on Thursday released ... Care Reconciliation Act. It differs significantly from the American Health Care Act, which the ... committee, or the House will have to take up the Senate version as-is, if ...
(Date:6/24/2017)... , ... June 24, 2017 , ... ... offering genetic testing for medications in select Florida and Texas doctors' offices and ... , This new application of genetic testing recognizes the role genes play in ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island Quality Institute ... Alerts and Dashboards, an innovative new service enabling healthcare providers to proactively coordinate ... Alerts and Dashboards provide near real-time data about patients admitted to and/or discharged ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... The Military ... president's nominee for deputy secretary of Veterans Affairs, retired Marine Col. Thomas G. Bowman. ... Affairs. , Bowman brings an intimacy with the issues and challenges veterans ...
(Date:6/23/2017)... ... , ... The Aesthetic Channel has recently highlighted Dr. Ben Talei’s unique approach ... proprietary technique that he calls the AuraLyft Facelift. The AuraLyft does more ... can expect to look refreshed, rejuvenated, and revitalized. , Dr. Talei’s unique approach ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... , June 14, 2017 The Bio ... City of Fremont and the ... the bio-pharma industry in California ... enabling executive networking, and fostering workforce development. The primary ... and growth of start-ups, as well as small and ...
(Date:6/12/2017)... 12, 2017 Kineta, Inc., a biotechnology company focused ... Vice President of R&D and Head of Virology Kristin ... Preparedness for the Northwest and Beyond meeting sponsored by ... 14, 2017 from 8:30-10:30 AM PDT at the Agora Conference ... Dr. Bedard will be joined by other leaders in ...
(Date:6/9/2017)... PALO ALTO, Calif. , June 9, 2017 /PRNewswire/ ... medical device company focused on the design, manufacture, sale ... updated the market on the progress of its commercial ... AeroForm is now available in more than one hundred ... country. AeroForm offers a needle-free alternative ...
Breaking Medicine Technology: